愿意使用长效注射式PrEP在PrEP的天真黑人和西班牙裔性别少数群体中使用长效注射式PrEP
Chukwuemeka N Okafor1, Lisa Eaton2, Ryan Watson2
1Department of Medicine, Division of Infectious Diseases, Long School of Medicine, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas, 78229-3900, USA. Okaforcn@uthscsa.edu.
AIDS and behavior
|March 25, 2024
概括
在黑人和西班牙裔性和性别少数群体 (SGM) 个人中评估了使用长效注射性暴露前预防 (LAI-PrEP) 的意愿. 准备剂污名与更低的意愿有关,而更多的性伴侣与更高的意愿使用LAI-PrEP相关.
科学领域:
- 公共卫生 公共卫生
- 预防艾滋病毒 预防艾滋病毒
- 性健康 性的健康
背景情况:
- 长效注射性暴露前预防 (LAI-PrEP) 提供了每日口服PrEP的替代方案,有可能改善坚持和减少耻辱感.
- 黑人和西班牙裔的性和性别少数群体 (SGM) 在美国受到艾滋病毒的影响不成比例,但关于他们愿意使用LAI-PrEP的数据有限.
研究的目的:
- 评估在没有使用PREP的黑人和西班牙裔SGM个体中使用LAI-PrEP的意愿.
- 在这个人群中确定与愿意使用LAI-PrEP相关的因素.
主要方法:
- 从从未使用过PrEP的黑人和西班牙裔SGM个人的全国样本中分析数据.
- 使用日志双项回归模型来确定与LAI-PrEP意愿相关的特征.
主要成果:
- 在380名参与者中,超过一半 (54%) 表示愿意使用LAI-PrEP.
- 准备剂污名与意愿降低有显著的关联 (PR=0.7,95% CI=0.6-0.9).
- 在过去12个月中,更多的性伴侣与增加的意愿有关 (PR=1.1,95% CI=1.0-1.2).
结论:
- 在未使用PrEP的黑人和西班牙裔SGM个体中,PrEP污名仍然是LAI-PrEP吸收的重要障碍.
- 需要有针对性的干预措施来解决PrEP的污名化问题,并在脆弱的SGM社区促进LAI-PrEP的使用.
相关概念视频
Sexually Transmitted Infections
1.7K
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
1.7K
Bioavailability Study Design: Healthy Subjects Versus Patients
216
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
216
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
475
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
475
Drug Dosing: Obese Patients
345
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
345
Insulin Formulations: Types and Delivery
1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.1K
Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K


